Quantinno Capital Management LP Buys 80,918 Shares of Johnson & Johnson (NYSE:JNJ)

Quantinno Capital Management LP raised its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 36.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 300,517 shares of the company's stock after buying an additional 80,918 shares during the quarter. Johnson & Johnson accounts for 0.4% of Quantinno Capital Management LP's investment portfolio, making the stock its 29th largest holding. Quantinno Capital Management LP's holdings in Johnson & Johnson were worth $43,461,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. IFS Advisors LLC lifted its stake in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after buying an additional 100 shares during the period. WealthTrak Capital Management LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $29,000. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $32,000. Finally, Conquis Financial LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $33,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE:JNJ traded up $1.76 during trading on Friday, reaching $151.37. The company's stock had a trading volume of 8,045,511 shares, compared to its average volume of 7,943,688. The firm has a market cap of $364.20 billion, a price-to-earnings ratio of 22.76, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a 50 day moving average of $156.56 and a 200-day moving average of $154.00. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.44%. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on JNJ. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Morgan Stanley upped their target price on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 16th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Finally, Argus raised Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Eleven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $170.88.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares of the company's stock, valued at $3,483,645.88. The trade was a 25.00% decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.